Literature DB >> 12472777

Urate transport via human PAH transporter hOAT1 and its gene structure.

Kimiyoshi Ichida1, Makoto Hosoyamada, Hiroaki Kimura, Michio Takeda, Yasunori Utsunomiya, Tatsuo Hosoya, Hitoshi Endou.   

Abstract

BACKGROUND: We recently cloned the human organic anion transporter 1 (hOAT1) as a p-aminohippurate (PAH) transporter. Whether urate is transported by the PAH transporter in humans remains unclear. Familial juvenile gouty nephropathy (FJGN) is thought to develop as a result of an abnormality in the urate transporter.
METHODS: To determine if hOAT1 transported urate, the cellular uptakes of PAH and urate were determined, as were the inhibition profiles of inorganic anions, and uricosuric and antiuricosuric agents using a mouse S2 cell line expressing hOAT1. The hOAT1 gene was cloned from a genomic library using full-length hOAT1-1 cDNA as a probe. The coding regions of the hOAT1 genes of two sisters with FJGN were sequenced. Also, immunohistochemical fluorescence analysis of hOAT1 in the kidney of the younger sister with FJGN was performed.
RESULTS: The Km and Vmax values of urate transport via hOAT1 were 943 +/- 84 micromol/L and 1286 +/- 162 pmol/mg protein/min, respectively. The order of the IC50 of urate transport via hOAT1 was benzbromarone < probenecid < salicylate or pyrazine carboxylic acid. The 10.9 kb hOAT1 gene was found to be interrupted by nine introns. Mutations in the coding region of the hOAT1 gene from the two sisters with FJGN were undetectable. Immunohistochemical fluorescent staining showed that hOAT1 in the kidney of the younger sister was similar to that of control individuals.
CONCLUSIONS: Our data show that hOAT1 transports urate, and the inhibition profiles of uricosuric and antiuricosuric agents are defined. hOAT1 is not responsible for FJGN in the two sisters examined in this study.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12472777     DOI: 10.1046/j.1523-1755.2003.00710.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  30 in total

1.  Involvement of uric acid transporters in alteration of serum uric acid level by angiotensin II receptor blockers.

Authors:  Masanobu Sato; Takashi Iwanaga; Hideaki Mamada; Toshio Ogihara; Hikaru Yabuuchi; Tomoji Maeda; Ikumi Tamai
Journal:  Pharm Res       Date:  2007-08-03       Impact factor: 4.200

Review 2.  Roles of organic anion transporters (OATs) and a urate transporter (URAT1) in the pathophysiology of human disease.

Authors:  Atsushi Enomoto; Hitoshi Endou
Journal:  Clin Exp Nephrol       Date:  2005-09       Impact factor: 2.801

Review 3.  Organic anion transporters of the SLC22 family: biopharmaceutical, physiological, and pathological roles.

Authors:  Ahsan N Rizwan; Gerhard Burckhardt
Journal:  Pharm Res       Date:  2007-03       Impact factor: 4.200

4.  Linkage of organic anion transporter-1 to metabolic pathways through integrated "omics"-driven network and functional analysis.

Authors:  Sun-Young Ahn; Neema Jamshidi; Monica L Mo; Wei Wu; Satish A Eraly; Ankur Dnyanmote; Kevin T Bush; Tom F Gallegos; Douglas H Sweet; Bernhard Ø Palsson; Sanjay K Nigam
Journal:  J Biol Chem       Date:  2011-07-12       Impact factor: 5.157

Review 5.  Physiology, structure, and regulation of the cloned organic anion transporters.

Authors:  C Srimaroeng; J L Perry; J B Pritchard
Journal:  Xenobiotica       Date:  2008-07       Impact factor: 1.908

Review 6.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

7.  Molecular cloning and functional analyses of OAT1 and OAT3 from cynomolgus monkey kidney.

Authors:  Harunobu Tahara; Masayuki Shono; Hiroyuki Kusuhara; Hajime Kinoshita; Eiichi Fuse; Akira Takadate; Masaki Otagiri; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2005-04-07       Impact factor: 4.200

8.  Multiple organic anion transporters contribute to net renal excretion of uric acid.

Authors:  Satish A Eraly; Volker Vallon; Timo Rieg; Jon A Gangoiti; William R Wikoff; Gary Siuzdak; Bruce A Barshop; Sanjay K Nigam
Journal:  Physiol Genomics       Date:  2008-02-12       Impact factor: 3.107

Review 9.  A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?

Authors:  Ming-Han H Lee; Garry G Graham; Kenneth M Williams; Richard O Day
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

10.  What lies behind serum urate concentration? Insights from genetic and genomic studies.

Authors:  Kimiyoshi Ichida
Journal:  Genome Med       Date:  2009-12-29       Impact factor: 11.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.